Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03286088
Other study ID # ICBE-2-15217
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 22, 2017
Est. completion date December 31, 2019

Study information

Verified date October 2021
Source Philips Electronics Nederland B.V. acting through Philips CTO organization
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study primarily aims to collect standard of care clinical data in a wide spectrum of simple to complex mitral valve regurgitation (MVR) cases to validate a post-processing stand-alone software prototype (QFlow), developed by Philips Research Paris (Medisys). Investigator does not intervene in the care of the patient, but simply collects standard of care images and measurements that are needed for the validation of the investigational software.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date December 31, 2019
Est. primary completion date July 31, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: - both genders - age between 18 and 85 years old (adult, senior) - sinus rhythm - hHemodynamic stable - mitral valve regurgitation (MVR) of any grade i.e., from mild to severe as determined by assessment of a qualifying TransThoracic Echocardiography (TTE) exam at Saint-Luc University Hospital - scheduled for TransEsophageal Echocardiography (TEE) at Saint-Luc University Hospital, as part of the subject's routine standard of care - subjects has functional capacity to give written informed consent Exclusion Criteria: - pregnancy - subject lacks functional capacity to give written informed consent belongs to a vulnerable population per investigator's judgment or subject has any kind of disorder that compromises his/her ability to give written informed consent and/or to comply with study procedures Among the120 subjects, there will be three (3) sub-groups as follows: - a first sub-group (A) of 50 subjects with all inclusion criteria and none of the exclusion criteria - a second sub-group (B) of 50 subjects with additional inclusion criterion: scheduled for cardiac Magnetic Resonance (cMR), as part of the subject's routine standard of care - a third sub-group (C) of 20 subjects with additional inclusion criterion: scheduled for MitraClip transcatheter mitral valve repair (MitraClip) procedure as part of the subject's routine standard of care

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
TransEsophageal Echocardiography and TransEsophageal Echocardiography
imaging as standard practice
Cardiac Magnetics Resonance
imaging as standard practice
MitraClip
imaging as standard practice

Locations

Country Name City State
Belgium Saint Luc University Hospital Brussels

Sponsors (1)

Lead Sponsor Collaborator
Philips Electronics Nederland B.V. acting through Philips CTO organization

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Central diastolic and systolic blood pressures images and measurements Day 1